FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Thursday

 

Treatment with Lemtrada Produces Sustained Reductions in Lesions and Brain Atrophy in Patients with Multiple Sclerosis

Data from two phase 3 clinical trials show the positive benefits observed in patient with multiple sclerosis (MS) via magnetic resonance imaging (MRI) from two years of treatment with Lemtrada are maintained at one year after completion of treatment.

Lemtrada is a monoclonal antibody that selectively targets CD52, resulting in the depletion of circulating T and B cells. 

Study results announced at the 2014 American Academy of Neurology annual meeting in Philadelphia, PA, demonstrated that MS patients in the CARE-MS I and CARE-MS II trials experienced improvements in key measures of disease activity, including reductions in brain lesions and atrophy. 

The CARE-MS I trial was a randomized two-year study of treatment-naive patients with active relapsing-remitting multiple sclerosis that compared treatment with Lemtrada to high-dose subcutaneous interferon beta-1a. The patients in the CARE-MS II trial had relapsed afterprior therapy. 

Patients in both studies received two courses of treatment: intravenous infusion on five consecutive days, followed by a second round administered on three consecutive days, 12 months later. 

Data included results from 349 patients from CARE-MS I and 393 patients from CARE-MS II. Some patients who showed evidence of disease activity during the year after the treatment period received retreatment retreatment with Lemtrada (18 percent from CARE-MS I and 20 percent from CARE-MS II). 

Patients received MRI scans at baseline and at 12, 24, and 36 months. 

Researchers reported that during one-year of follow-up, “more than 70% of patients were free of MRI activity indicative of acute inflammation, defined as gd-enhancing or new or enlarging T2 hyperintense lesions.” They also reported that the rate of brain atrophy was reduced following two years of treatment continued to slow during one-year follow-up. 

Patients in CARE-MS I who were treated with Lemtrada had significantly reduced annualized relapse rates compared to patients treated with interferon beta-1a. Measures of disability progression were similar across treatment groups. 
Patients in CARE-MS II who were treated with Lemtrada also had significantly reduced annualized relapse rates compared to patients treated with interferon beta-1a, as well as significantly slower rates of accumulation of disability.

Story Source: The above story is based on materials provided by HCPLIVE
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News